ScinoPharm Taiwan Ltd (1789)

Taiwan

Currency in TWD

16.80

+0.05(+0.30%)

Closed·01/08

Fair Value

Unlock Value

Day's Range

16.40

16.80

52 wk Range

16.25

25.80

1789 Financial Summary

A brief financial summary of ScinoPharm Taiwan Ltd as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Key Ratios

P/E Ratio55.29

Price/Book1.27

Debt / Equity6.52%

Return on Equity2.31%

Dividend Yield2.08%

EBITDA792.08M

Fair ValueUnlock

Fair Value UpsideUnlock

Statements Highlights

Period Ending:

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

Income Statement

Total Revenues

aa.aa

3,082.93

2,762.34

3,264.05

3,186.08

3,406.28

Gross Profit

aa.aa

1,317.46

1,280.49

1,250.77

1,215.99

1,300.21

Operating Income

aa.aa

375.72

288.62

405.5

314.49

321.04

Net Income

aa.aa

282.07

243.47

353.22

287.06

339.35

Balance Sheet

Total Assets

aa.aa

11,846.76

11,691.18

11,911.18

11,721.59

11,942.74

Total Current Liabilities

aa.aa

686.65

556.31

803.09

729.45

767.68

Total Equity

aa.aa

10,529.4

10,511.05

10,450.05

10,364.43

10,525.8

Cash Flow

Levered Free Cash Flow

aa.aa

672.65

91.58

465.34

-74

424.85

Cash from Operations

aa.aa

946.31

509.82

773.79

231.13

750.91

Cash from Investing

aa.aa

241.72

-69.98

-253.62

-233.29

-293.38

Cash from Financing

aa.aa

-444.91

-412.77

-314.83

-340.98

-244.89

Net Change in Cash

aa.aa

749.97

25.97

213.79

-353.19

224.46

* In Millions of TWD (except for per share items)

Dividends

Payout Ratio

Payout ratio (TTM)

Earnings retained

EPS 0.31%

Dividend Yield

2.06%

Industry Median 2.54%

Annualised payout

0.35

Paid annually

5-Years Growth

+5.33%

Growth Streak

Unlock

Analyst Ratings

0 Buy

1 Hold

0 Sell

Ratings:

1 analysts

Overall Consensus

Neutral

Analysts 12-Month Price Target:

Average 24.00

(+42.86% Upside)

Earnings

Latest Release

May 07, 2025

EPS / Forecast

0.04 / --

Revenue / Forecast

650.00M / --

EPS Revisions

Unlock

Last 90 days

FAQ

What were SPT's earnings for the latest quarter?

The SPT EPS (TTM) is 0.31. SPT reported sales of 686.37, net income of 46.02, and EPS of 0.04 for the latest quarter.

What was SPT's net income for the latest quarter?

SPT's net income for the latest quarter was 46.02.

How did SPT's performance compare year-over-year in the latest quarter?

The company's revenue moved from 1,036.48 in the previous quarter to 686.37 in the latest quarter, and net income moved from 97.34 to 46.02 compared to the previous quarter.

What is SPT's net profit margin on a TTM basis?

SPT's trailing twelve months (TTM) net profit margin is 9.96%.

How does SPT's debt to equity ratio compare to industry standards?

SPT's total debt-to-equity ratio is 6.52%.

What is SPT's return on investment on a TTM basis?

SPT's trailing twelve months (TTM) return on investment (ROI) is 2.31%.

Did SPT gain or lose cash last quarter?

In the latest quarter, SPT's net change in cash was -1,068.28 million.

What were SPT's total assets and liabilities in the latest quarter?

As of the latest quarter, SPT reported total assets of 12,059.67 million and total liabilities of 735.32 million.

How has SPT's total revenue grown this year?

SPT's total revenue was 1,036.48 in the previous quarter and 686.37 in the latest quarter.

What is SPT's gross margin on a TTM basis?

SPT's trailing twelve months (TTM) gross margin is 36.61%.

What was SPT's revenue per share for the latest quarter?

SPT's revenue per share for the latest quarter was 22.77.

NSE 30

5,288.95

+103.40

+1.99%

NSE All Share

144,071.77

+2,808.71

+1.99%

US 30

44,196.50

+22.9

+0.05%

US 500

6,334.10

+4.2

+0.07%

FTSE 100

9,128.30

+59.72

+0.66%

DAX

23,757.69

+331.72

+1.42%

South Africa Top 40

91,801.90

+1,661.35

+1.84%

Market Movers

Name	Last	Chg. %	Vol.
Fcmb	11.850	+9.72%	84.95M
Fidelitybk	21.200	0.00%	45.43M
Access Holdings	27.80	-0.71%	28.29M
Guaranty Trust Holding	100.00	+0.50%	27.39M
Zenith Bank	76.90	+0.52%	24.00M
Dangote Cement	577.00	+9.22%	2.90M
MTN Nigeria	480.00	0.00%	1.50M

Name	Last	Chg. %	Vol.
Lasaco Assurance PLC	2.86	+10.00%	5.02M
Royalex	1.65	+10.00%	5.00M
UPDC	5.94	+10.00%	5.83M
UAC Of Nigeria	97.10	+9.97%	3.19M
Sovereign Trust Insurance Plc	1.88	+9.94%	7.95M
Champion Brew	13.75	+9.91%	1.65M
Ellah Lakes	10.65	+9.91%	26.64M

Name	Last	Chg. %	Vol.
Academy Press	9.90	-10.00%	637.00K
Transcorp Power	288.00	-10.00%	277.63K
John Holt PLC	6.60	-9.59%	965.49K
Total Nig	640.00	-9.22%	143.26K
ETI	34.00	-9.21%	2.40M
CWG	17.000	-9.09%	5.62M
Dangote Sugar	62.00	-6.27%	5.46M

Trending Stocks

Name	Last	Chg. %	Vol.
MTN Nigeria	480.00	0.00%	1.50M
UAC Of Nigeria	97.10	+9.97%	3.19M
Wema Bank	24.70	+3.35%	18.72M
BUA Cement	155.00	+4.73%	1.62M
Aradel Holdings	514.00	-1.15%	1.22M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaaaaaaaaaa	577.00	+33.92%	772.72
Aaa A Aaaa Aaaaaaaa	67.00	+26.16%	84.53
Aaaaaaaaa A	155.00	+24.00%	192.20
Aaaaaaa Aaa Aaaaaa	640.00	+15.53%	739.39

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

ScinoPharm Taiwan Ltd (1789)

1789 Financial Summary

Key Ratios

Statements Highlights

Dividends

Analyst Ratings

Analysts 12-Month Price Target:

Earnings

FAQ

What were SPT's earnings for the latest quarter?

What was SPT's net income for the latest quarter?

How did SPT's performance compare year-over-year in the latest quarter?

What is SPT's net profit margin on a TTM basis?

How does SPT's debt to equity ratio compare to industry standards?

What is SPT's return on investment on a TTM basis?

Did SPT gain or lose cash last quarter?

What were SPT's total assets and liabilities in the latest quarter?

How has SPT's total revenue grown this year?

What is SPT's gross margin on a TTM basis?

What was SPT's revenue per share for the latest quarter?

Trending Stocks